Lafaval

Tadalafil, the active ingredient in Lafaval, is a Phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It treats erectile dysfunction and is also indicated for benign prostatic hyperplasia and pulmonary arterial hypertension in adult patients.

GNH USA supplies Lafaval as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lafaval, a PDE5 inhibitor, is used in several clinical conditions that involve smooth‑muscle relaxation and improved blood flow. - Erectile dysfunction: enhances the ability to achieve and maintain an erection suitable for sexual activity. - Benign prostatic hyperplasia: reduces urinary frequency and improves flow by relaxing prostate smooth muscle. - Pulmonary arterial hypertension: increases exercise capacity by lowering pulmonary vascular resistance.

Tadalafil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Flushing: warmth and redness of the face or neck. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: blocked or runny nose. - Back pain: aching discomfort in the lower back. - Myalgia: muscle aches, often in the limbs.

Serious or Rare Side Effects: - Sudden vision loss: non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: unexplained decrease in hearing acuity. - Priapism: prolonged erection lasting more than 4 hours. - Severe hypotension: marked drop in blood pressure causing dizziness. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Chest pain: possible indication of cardiac ischemia.

Before prescribing Lafaval, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate for recent myocardial infarction or unstable angina. - Concomitant nitrate use: avoid due to risk of profound hypotension. - Severe hepatic impairment: dose adjustment may be required. - Renal impairment: monitor patients with moderate to severe kidney disease. - Retinitis pigmentosa: contraindicated in patients with this inherited retinal disorder. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Tadalafil can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Nitrates: concurrent use may cause dangerous blood‑pressure drops. - Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect. - Alpha‑blockers (certain formulations): risk of severe hypotension.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (ketoconazole, itraconazole): increase tadalafil exposure. - CYP3A4 inducers (rifampin, carbamazepine): reduce tadalafil effectiveness. - Antihypertensive agents: may enhance blood‑pressure lowering. - Alcohol: can potentiate hypotensive effects. - Other PDE5 inhibitors: combined use raises risk of priapism.